JCCVS
Journal of Cardiology & Cardiovascular Surgery

Journal of Cardiology & Cardiovascular Surgery scientific, open-access, double-blind peer-reviewed journal covering a wide spectrum of topics in cardiology and cardiovascular surgery. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-1397
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review
Abstract
Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.

Keywords : Sodium-glucose co-transporter, diabetes mellitus, heart failure, kidney disease

Download Article


1. Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein2 (SGLT2) Inhibitors. In:StatPearls. Treasure Island (FL): StatPearlsPublishing; September 23, 2022.
2. Kaushal S, Singh H, Thangaraju P, Singh J. Canagliflozin: A NovelSGLT2 Inhibitor for Type 2 Diabetes Mellitus.N Am J Med Sci.2014;6(3):107-113. doi:10.4103/1947-2714.128471
3. Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: anupdate.Curr Opin Nephrol Hypertens. 2020;29(2):190-198. doi:10.1097/MNH.0000000000000584
4. Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes [publishedcorrection appears in. Drugs. 2019 Dec;79(18):2013.
5. Frampton JE. Empagliflozin: A Review in Type 2 Diabetes. Drugs.2018;78(10):1037-1048. doi:10.1007/s40265-018-0937-z.
6. Sizar O, Podder V, Talati R. Empagliflozin. In:StatPearls. TreasureIsland (FL): StatPearls Publishing; June 5, 2022.
7. Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in ClinicalPractice for Heart Failure Prevention and Treatment: Beyond Type2 Diabetes. A Narrative Review.Adv Ther. 2022;39(2):845-861.doi:10.1007/s12325-021-01989-z
8. Powell J, Garland SG. Ertugliflozin: A New Option in the SGLT-2Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.AnnPharmacother. 2019;53(5):478-485. doi:10.1177/1060028018818829
9. Gyimesi G, Pujol-Giménez J, Kanai Y, Hediger MA. Sodium-coupledglucose transport, the SLC5 family, and therapeutically relevantinhibitors: from molecular discovery to clinical application.PflugersArch. 2020;472(9):1177-1206. doi:10.1007/s00424-020-02433-x.
10. Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters:Functional properties and pharmaceutical potential.J Diabetes Investig.2020;11(4):770-782. doi:10.1111/jdi.13255).
11. Wright EM, Loo DD, Hirayama BA. Biology of human sodiumglucose transporters.Physiol Rev. 2011;91(2):733-794. doi:10.1152/physrev.00055.2009.
12. Thorens B, Mueckler M. Glucose transporters in the 21st Century.AmJ Physiol Endocrinol Metab. 2010;298(2):E141-E145. doi:10.1152/ajpendo.00712.2009.
13. Goksu UA. Sodyum Glukoz ko-transporter tip 2 inhibitörleri: Diyabettedavisinde yeni seçenek. Namık Kemal Tıp Dergisi. 2018;6(3):122-139
14. Mather A, Pollock C. Glucose handling by the kidney.Kidney Int Suppl.2011;(120):S1-S6. doi:10.1038/ki.2010.509.
15. Girard J. Rôle des reins dans l’homéostasie du glucose. Implicationdu cotransporteur sodium-glucose SGLT2dans le traitement dudiabète [Role of the kidneys in glucose homeostasis. Implicationof sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitustreatment].Nephrol Ther. 2017;13 Suppl 1:S35-S41. doi:10.1016/j.nephro.2017.01.006
16. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibitonly 30-50% of renal glucose reabsorption in humans?.Diabetes.2012;61(9):2199-2204. doi:10.2337/db12-0052
17. Davidson JA, Kuritzky L. Sodium glucose co-transporter 2 inhibitorsand their mechanism for improving glycemia in patients withtype 2 diabetes.Postgrad Med. 2014;126(6):33-48. doi:10.3810/pgm.2014.10.2819
18. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure:Potential Mechanisms, Clinical Applications, and Summary ofClinical Trials.Circulation. 2017;136(17):1643-1658. doi:10.1161/CIRCULATIONAHA.117.030012
19. Nathan DM, Buse JB, Davidson MB, et al. Medical managementof hyperglycemia in type 2 diabetes: a consensus algorithm for theinitiation and adjustment of therapy: a consensus statement of theAmerican Diabetes Association and the European Association for theStudy of Diabetes.Diabetes Care. 2009;32(1):193-203. doi:10.2337/dc08-9025.
20. European Medicines Agency. Jardiance brochure empagliflozin).http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/European_Commission_final_decision/WC500206515.pdf. Accessed March 2017.
21. Deeks ED, Scheen AJ. Canagliflozin: A Review in Type 2Diabetes.Drugs. 2017;77(14):1577-1592. doi:10.1007/s40265-017-0801-6
22. Ganesan K, Rana MBM, Sultan S. Oral Hypoglycemic Medications.In:StatPearls. Treasure Island (FL): StatPearls Publishing; May 8, 2022.
23. Marrs JC, Anderson SL. Ertugliflozin in the treatment of type 2 diabetesmellitus.Drugs Context. 2020;9:2020-7-4. doi:10.7573/dic.2020-7-4
24. Isaacs M, Tonks KT, Greenfield JR. Euglycaemic diabetic ketoacidosisin patients using sodium-glucose co-transporter 2 inhibitors.InternMed J. 2017;47(6):701-704. doi:10.1111/imj.13442
25. Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operativeconsiderations.Anaesthesia. 2018;73(8):1008-1018. doi:10.1111/anae.14251
26. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N.SGLT2 Inhibitors: A Review of Their Antidiabetic and CardioprotectiveEffects.Int J Environ Res Public Health. 2019;16(16):2965. doi:10.3390/ijerph16162965
27. Scheen AJ. An update on the safety of SGLT2 inhibitors.Expert OpinDrug Saf. 2019;18(4):295-311. doi:10.1080/14740338.2019.1602116
28. Scheen AJ. Efficacy and safety profile of SGLT2 inhibitors in patientswith type 2 diabetes and chronic kidney disease.Expert Opin Drug Saf.2020;19(3):243-256. doi:10.1080/14740338.2020.1733967
29. McGill JB, Subramanian S. Safety of Sodium-Glucose Co-Transporter2 Inhibitors.Am J Cardiol. 2019;124 Suppl 1:S45-S52. doi:10.1016/j.amjcard.2019.10.029
Article available in :
Volume 1, Issue 1, 2023
Page : 10-13
https://doi.org/10.51271/JCCVS-0003
Article Information
Received : 19 Mar 2023
Accepted : 30 Mar 2023
Published : 30 Mar 2023
Corresponding Author :

Bülent Erdoğan: Gulhane Training and Research Hospital, Department of Nephrology, Ankara, Turkey

[email protected]
Citation : Demir ME, Ercan Z, Erdogan B. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review. J Cardiol Cardiovasc Surg. 2023;1(1):10-13.

Read: 321
Cited: 0
Download : 222
_Footer